Corxel Pharmaceuticals Hong Kong

Corxel is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with cardiometabolic diseases worldwide. The company's management team has extensive experience and an outstanding track record in identifying, in-licensing, and developing high-quality clinical candidates targeting validated mechanisms of action (MoA) and established pathways. Corxel’s diversified clinical-stage pipeline has the potential to redefine treatment standards and address key limitations of current therapies for various cardiometabolic diseases. Key products include CX11, JX10, and JX09, indicated for obesity and type 2 diabetes, acute ischemic stroke, and hypertension, respectively.